LeMaitre Vascular, Inc. LMAT
80.95 USD +0.06 (+0.07%)
Nov 9, 2026, 12:51 PM EST
79.98 Day range 81.92
78.22 52-week range 118.01
- YTD
- -0.19%
- 1 year
- -6.76%
News
seekingalpha.com LeMaitre Vascular, Inc. (LMAT) Q3 2026 Earnings Call Transcript LeMaitre Vascular, Inc. ( LMAT ) Q3 2026 Earnings Call November 4, 2026 5:00 PM EST Company Participants Dorian LeBlanc - Chief Financial Officer George LeMaitre - Chairman & CEO Conference Call…
benzinga.com Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Lowers Price Target to $86 Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and lowers the price target from $94 to $86.
benzinga.com Citizens Maintains Market Outperform on LeMaitre Vascular, Lowers Price Target to $110 Citizens analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperform and lowers the price target from $127 to $110.
marketbeat.com LeMaitre Vascular Q3 Earnings Call Highlights LeMaitre Vascular NASDAQ: LMAT reported 12% organic sales growth in the third quarter of 2026, driven by higher prices and unit volumes, while reiterating its full-year organic growth outlook and…
zacks.com LeMaitre Vascular (LMAT) Misses Q3 Earnings Estimates LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.65 per share, missing the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.62 per share a year ago.
benzinga.com LeMaitre Vascular Q3 2026 Earnings Call Transcript LeMaitre Vascular (NASDAQ:LMAT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com LeMaitre Vascular Lowers FY2026 GAAP EPS Guidance from $2.84-$2.94 to $2.77-$2.82 vs $2.87 Est; Narrows FY2026 Sales Guidance from $274.300M-$278.300M to $274.800M-$276.800M vs $276.539M Est LeMaitre Vascular (NASDAQ:LMAT) lowers FY2026 GAAP EPS guidance from $2.84-$2.94 to $2.77-$2.82 vs $2.87 analyst estimate. Narrows FY2026 sales outlook from $274.300 million-$278.300 million to…
benzinga.com LeMaitre Vascular Lowers Q4 GAAP EPS Guidance from $0.75-$0.81 to $0.70-$0.75 vs $0.78 Est; Lowers Q4 Sales Guidance from $71.100M-$73.100M to $69.900M-$71.900M vs $72.325M Est LeMaitre Vascular (NASDAQ:LMAT) lowers Q4 GAAP EPS guidance from $0.75-$0.81 to $0.70-$0.75 vs $0.78 analyst estimate. Lowers Q4 sales outlook from $71.100 million-$73.100 million to $69.900…
globenewswire.com LeMaitre Q3 2026 Financial Results BURLINGTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a…- benzinga.com L3Harris Technologies Receives 7-Year, $4.7B Lockheed Martin Contract To Produce Propulsion Systems For PAC-3 Missile Segment Enhancement Interceptor L3Harris Technologies (NYSE: LHX) has received an undefinitized contract award from Lockheed Martin, valued at $4.7 billion over seven years, to produce propulsion systems for the PAC-3® Missile…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 107.0% to $2.65 during Wednesday's regular session. The company's market cap stands at $60.6 million. Bluejay Diagnostics (NASDAQ:BJDX)…
benzinga.com Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Lowers Price Target to $94 Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and lowers the price target from $104 to $94.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session. American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their…
benzinga.com LeMaitre Vascular Sees Q4 GAAP EPS $0.75-$0.81 vs $0.78 Est; Sees Sales $71.100M-$73.100M vs $72.745M Est LeMaitre Vascular (NASDAQ:LMAT) is looking for Q4 GAAP EPS of $0.75-$0.81 vs $0.78 analyst estimate. sees sales of $71.100 million-$73.100 million vs $72.745 million analyst estimate.- benzinga.com LeMaitre Vascular Sees Q3 GAAP EPS $0.66-$0.71 vs $0.73 Est; Sees Sales $66.300M-$68.300M vs $69.246M Est LeMaitre Vascular (NASDAQ:LMAT) is looking for Q3 GAAP EPS of $0.66-$0.71 vs $0.73 analyst estimate. sees sales of $66.300 million-$68.300 million vs $69.246 million analyst estimate.
benzinga.com LeMaitre Vascular Lowers FY2026 GAAP EPS Guidance from $2.93-$3.08 to $2.84-$2.94 vs $2.97 Est; Lowers FY2026 Sales Guidance from $277.000M-$283.000M to $274.300M-$278.300M vs $279.948M Est LeMaitre Vascular (NASDAQ:LMAT) lowers FY2026 GAAP EPS guidance from $2.93-$3.08 to $2.84-$2.94 vs $2.97 analyst estimate. Lowers FY2026 sales outlook from $277.000 million-$283.000 million to…- benzinga.com LeMaitre Vascular Q2 EPS $0.74 Misses $0.79 Estimate, Sales $70.382M Miss $70.973M Estimate LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.74 per share which missed the analyst consensus estimate of $0.79 by 6.33 percent. This is a 23.33 percent increase over earnings of…
- benzinga.com Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $120 Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and raises the price target from $105 to $120.
benzinga.com Citizens Maintains Market Outperform on LeMaitre Vascular, Raises Price Target to $127 Citizens analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperform and raises the price target from $118 to $127.- benzinga.com Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Raises Price Target to $104 Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and raises the price target from $94 to $104.
- benzinga.com LeMaitre Vascular Reports Q1 2026 Results: Full Earnings Call Transcript
benzinga.com LeMaitre Vascular Sees Q2 GAAP EPS $0.79-$0.84 vs $0.75 Est; Sees Sales $70.500M-$72.500M vs $71.105M Est LeMaitre Vascular (NASDAQ:LMAT) is looking for Q2 GAAP EPS of $0.79-$0.84 vs $0.75 analyst estimate. sees sales of $70.500 million-$72.500 million vs $71.105 million analyst estimate.- benzinga.com LeMaitre Vascular Raises FY2026 GAAP EPS Guidance from $2.81-$3.01 to $2.93-$3.08 vs $2.90 Est; Narrows FY2026 Sales Guidance from $276.000M-$284.000M to $277.000M-$283.000M vs $279.492M Est LeMaitre Vascular (NASDAQ:LMAT) raises FY2026 GAAP EPS guidance from $2.81-$3.01 to $2.93-$3.08 vs $2.90 analyst estimate. Narrows FY2026 sales outlook from $276.000 million-$284.000 million to…
- benzinga.com LeMaitre Vascular Q1 EPS $0.68 Beats $0.66 Estimate, Sales $66.551M Beat $66.530M Estimate LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.66 by 3.03 percent. This is a 41.67 percent increase over earnings of…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $105 Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and raises the price target from $95 to $105.
benzinga.com J M Smucker, Krispy Kreme, Shake Shack, Accenture And Other Big Stocks Moving Higher On Thursday 
benzinga.com Breaking Down LeMaitre Vascular: 4 Analysts Share Their Views - benzinga.com Roth Capital Reiterates Buy on LeMaitre Vascular, Raises Price Target to $117 Roth Capital analyst Kyle Bauser reiterates LeMaitre Vascular (NASDAQ:LMAT) with a Buy and raises the price target from $108 to $117.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Raises Price Target to $94 Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and raises the price target from $87 to $94.
benzinga.com Citizens Maintains Market Outperform on LeMaitre Vascular, Raises Price Target to $118 Citizens analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperform and raises the price target from $113 to $118.- benzinga.com LeMaitre Vascular Sees FY2026 GAAP EPS $2.81-$3.01 vs $2.58 Est; Sees Sales $276.000M-$284.000M vs $270.499M Est LeMaitre Vascular (NASDAQ:LMAT) is looking for FY2026 GAAP EPS of $2.81-$3.01 vs $2.58 analyst estimate. sees sales of $276.000 million-$284.000 million vs $270.499 million analyst estimate.
- benzinga.com LeMaitre Vascular Sees Q1 GAAP EPS $0.64-$0.69 vs $0.61 Est; Sees Sales $65.600M-$67.600M vs $65.855M Est LeMaitre Vascular (NASDAQ:LMAT) is looking for Q1 GAAP EPS of $0.64-$0.69 vs $0.61 analyst estimate. sees sales of $65.600 million-$67.600 million vs $65.855 million analyst estimate.
benzinga.com LeMaitre Vascular: Q4 Earnings Insights - benzinga.com LeMaitre Vascular Q4 EPS $0.68 Beats $0.66 Estimate, Sales $64.453M Beat $62.823M Estimate LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.66 by 2.41 percent. This is a 38.78 percent increase over earnings of…
- benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com Exploring LeMaitre Vascular's Earnings Expectations - benzinga.com Barrington Research Maintains Outperform on LeMaitre Vascular, Maintains $95 Price Target Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and maintains $95 price target.
- benzinga.com Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Lowers Price Target to $93 Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and lowers the price target from $97 to $93.
- benzinga.com LeMaitre Vascular Raises FY2025 GAAP EPS Guidance from $2.23-$2.37 to $2.48-$2.53 vs $2.27 Est; Lowers FY2025 Sales Guidance from $248.000M-$254.000M to $247.000M-$249.000M vs $250.617M Est LeMaitre Vascular (NASDAQ:LMAT) raises FY2025 GAAP EPS guidance from $2.23-$2.37 to $2.48-$2.53 vs $2.27 analyst estimate. Lowers FY2025 sales outlook from $248.000 million-$254.000 million to…
- benzinga.com LeMaitre Vascular Sees Q4 GAAP EPS $0.64-$0.69 vs $0.63 Est; Sees Sales $61.800M-$63.800M vs $64.324M Est LeMaitre Vascular (NASDAQ:LMAT) is looking for Q4 GAAP EPS of $0.64-$0.69 vs $0.63 analyst estimate. sees sales of $61.800 million-$63.800 million vs $64.324 million analyst estimate.
- benzinga.com LeMaitre Vascular Q3 EPS $0.75 Beats $0.57 Estimate, Sales $61.046M Miss $62.181M Estimate LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.57 by 32.51 percent. This is a 53.06 percent increase over earnings of…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Roth Capital Reinstates Buy on LeMaitre Vascular, Announces $108 Price Target Roth Capital analyst Kyle Bauser reinstates LeMaitre Vascular (NASDAQ:LMAT) with a Buy and announces $108 price target.
- benzinga.com Earnings Scheduled For August 5, 2025
- benzinga.com Earnings Scheduled For May 1, 2025
- benzinga.com Earnings Scheduled For February 27, 2025
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday